As we approach the crucial #euparliament vote on New Genomic Techniques (#NGT) next 24th January, at HRB, we recognize this as an important moment, not only for our industry but also for #global#agriculture.
We are committed to innovation and responsible science, so we would like to constructively reflect and bridge the diverse viewpoints in this #debate.
The unprecedented challenge of the #covid19 pandemic saw the world come together to rapidly develop and deploy vaccines. This example showcased our collective ability to respond swiftly to global emergencies with scientific innovation. We see a parallel opportunity in addressing other challenges, such as #climatechange or a responsible and sustainable #food#supply chain. Despite the difference in immediacy between these threats, the need for swift and collaborative action remains essential. The majority of the scientific community, through examples such as the recent open letters signed by world-renowned scientists, advocates for NGTs, highlighting their potential to ultimately transform agriculture in a sustainable way.
However, we also understand and respect the concerns raised about NGTs, including their equivalence to conventional breeds, potential for unintended effects, and the role of patents. Addressing these concerns while ensuring that the innovation is quickly deployed for sustainability demands a solution-oriented conversation between proponents and sceptics of NGTs.
At HRB, we believe in a future where innovation in genome editing takes place within a framework of robust regulation and transparency. As the EU decision nears, we remain committed to safe, sustainable solutions and an open, informed dialogue on this crucial subject.